Miniati D N, Robbins R C
Department of Cardiothoracic Surgery, Stanford University School of Medicine, California 94305, USA.
J Card Surg. 2000 Mar-Apr;15(2):129-35.
Heart and lung allograft dysfunction continues to be a problem in thoracic transplantation. Although medical therapy is often sufficient to restore allograft function, occasionally more invasive means are required. Mechanical assist devices, inhaled nitric oxide (iNO), and extracorporeal membrane oxygenation (ECMO) have been used with a modest degree of success in cases of refractory heart, lung, and heart-lung allograft failure. Allograft failure secondary to pulmonary hypertension often responds to iNO concentrations between 5 and 70 ppm without major toxicity. More severe cases may require mechanical assist devices or ECMO and carry higher risks of complications such as bleeding, neurological injury, and death. Utilization of and weaning from these interventions require intensive monitoring. Randomized, prospective studies are not ethically feasible, but case reports and patient series indicate the usefulness of mechanical circulatory support, iNO, and ECMO. This review focuses on the indications, complications, and patient survival rates associated with these modalities.
心肺移植功能障碍仍是胸外科移植中的一个问题。尽管药物治疗通常足以恢复移植器官的功能,但偶尔需要更具侵入性的手段。机械辅助装置、吸入一氧化氮(iNO)和体外膜肺氧合(ECMO)在难治性心脏、肺和心肺移植失败的病例中使用取得了一定程度的成功。继发于肺动脉高压的移植器官功能衰竭通常对5至70 ppm的iNO浓度有反应且无重大毒性。更严重的病例可能需要机械辅助装置或ECMO,并伴有更高的并发症风险,如出血、神经损伤和死亡。这些干预措施的使用和撤离需要密切监测。随机前瞻性研究在伦理上不可行,但病例报告和患者系列表明机械循环支持、iNO和ECMO是有用的。本综述重点关注与这些治疗方式相关的适应症、并发症和患者生存率。